Is DCO a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Ducommun (DCO) rests on Missile and defense electronics demand: Electronic Systems grew about 20% year over year in the second quarter of 2026, led by missile programs including PAC-3 and SM-6 plus F-15 work. The bear case rests on program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them. Analysts covering it publish targets from $150.00 to $222.00 against a $201.39 price, so even the professionals disagree by 36% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Ducommun Incorporated is a Santa Ana, California supplier of engineered products and manufacturing services to aerospace and defense customers. It runs two segments. Electronic Systems, the larger one at roughly 58% of second-quarter 2026 revenue, makes circuit card assemblies, wire harnesses and cable, radar and microwave subsystems, and printed circuit boards for missiles, radar, avionics and space hardware. Structural Systems makes metal and composite airframe structures, engine components and titanium parts. The company is one of the oldest continuously operating businesses in California, founded in 1849, and it sits a tier below the primes: it sells to Raytheon, Lockheed Martin, Boeing, Airbus, Northrop Grumman, Spirit AeroSystems and the engine makers rather than to governments or airlines directly. A deliberate shift over the past few years has been toward proprietary engineered products and aftermarket work, which reached about 23% of revenue over the trailing year versus roughly 15% in 2022. The investment picture is a small-cap industrial being repriced as a defense electronics compounder. Revenue is about $865 million on a trailing basis, second-quarter 2026 revenue hit a record $224.5 million (up about 12% year over year), gross margin reached 28.0% and adjusted EBITDA margin reached 17.1%, within reach of the 18% target management set under its Vision 2027 plan. Remaining performance obligations hit an all-time high near $1.2 billion on a 1.4x book-to-bill, with military and space accounting for about 62% of that backlog and commercial aerospace about 36%. The market has paid for this: the stock went from roughly $137 in early May 2026 to about $201 in August, and at a ~$3.0 billion market cap it trades near 3.5x trailing sales, a multiple that leaves no slack. Cutting against the story, Ducommun disclosed in May 2026 that a stock-based compensation timing error made its 2024 and 2025 financial statements unreliable, restated them, and reported a material weakness in internal control over financial reporting, which drew law-firm investigations.
The bull case: what would have to be true for $222.00
The most optimistic published target on DCO is $222.00, +10.2% from the $201.39 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Missile and defense electronics demand.
Electronic Systems grew about 20% year over year in the second quarter of 2026, led by missile programs including PAC-3 and SM-6 plus F-15 work. Restocking of interceptor inventories and multi-year procurement contracts give this content unusually long visibility for a supplier of Ducommun's size. Military and space is about 62% of the record $1.2 billion remaining performance obligation balance, so the defense half of the business is what currently sets the growth rate.
2. The commercial narrowbody rate ramp.
Structural Systems is levered to Boeing 737 MAX and Airbus A320 build rates, and that segment grew only about 2% in the second quarter against roughly 20% at Electronic Systems. If Boeing sustains higher MAX output and Airbus holds its A320 ramp, the structures business is where the incremental revenue and fixed-cost absorption would show up. This is also the piece that has held the consolidated growth rate down, so the commercial recovery is closer to an option on the thesis than a delivered part of it.
3. Vision 2027 and the engineered-products mix shift.
Vision 2027 targets roughly $1 billion of revenue, an 18% adjusted EBITDA margin and 25%-plus of sales from proprietary engineered products. Adjusted EBITDA margin of 17.1% and engineered products at about 23% of revenue say the plan is most of the way there, driven by strategic pricing, exiting low-margin work and a richer product mix. Whether the margin holds after the easy pricing actions are done is the open question, because a supplier's pricing power is only as durable as its customers' tolerance for it.
4. Balance sheet and bolt-on acquisitions.
Total debt was about $276 million against roughly $40 million of cash at the end of the second quarter, a manageable load against a rising EBITDA base. Ducommun has historically bought small engineered-products businesses to move mix upward rather than to add volume. Continued deleveraging plus tuck-in deals in higher-margin product lines is the stated path to the revenue target, and it is also where execution risk concentrates.
The bear case: what would have to be true for $150.00
The most pessimistic published target is $150.00, -25.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Ducommun is worth if the risks below bite instead of the drivers above.
Program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them. Its customer list is short and includes Boeing, whose production has been unsteady, so a rate cut, a strike or a program termination flows straight through. The accounting is a live issue: the company said in May 2026 that its 2024 and 2025 statements should no longer be relied upon because of a stock-based compensation timing error, restated them, disclosed a material weakness in internal control over financial reporting, and at least two plaintiffs' firms opened investigations, which raises the odds of litigation and of further remediation cost. Defense revenue depends on appropriations and on continued urgency around munitions restocking, both of which are political rather than commercial variables. Finally, at roughly $3 billion of market value on about $865 million of sales, the shares already price the Vision 2027 margin outcome, so a missed quarter on Structural Systems or a slip in the margin trajectory has more room to hurt than to help.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding DCO already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on DCO
5 analysts cover DCO, with an average target of $197.80 (-1.8% against $201.39) and a split of 4 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the DCO forecast and price target page.
How is DCO valued? (as of August 2026)
Snapshot for DCO as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$865 million
- Q2 2026 revenue: ~$224.5 million, up ~12% year over year
- Gross margin (Q2 2026): ~28.0%, a record
- Adjusted EBITDA margin (Q2 2026): ~17.1%, versus the ~18% Vision 2027 target
- Remaining performance obligations: ~$1.2 billion, book-to-bill ~1.4x
- Market cap / price to sales: ~$3.0 billion at ~$201 a share, ~3.5x trailing sales
Ducommun is priced like a defense electronics grower rather than a build-to-print machine shop, which is the whole argument of the mix shift. Trailing earnings-based multiples are high (in the 40s range) because GAAP net income is still small against a $3 billion market value, and the bull case rests on that gap closing as the 18% EBITDA target lands and engineered products pass a quarter of sales. Debt of about $276 million against roughly $40 million of cash is not a constraint at current EBITDA, but the valuation assumes the margin plan finishes on schedule.
How do you decide if DCO is a buy?
Rather than asking whether DCO is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold DCO indirectly through an index or sector ETF before adding more.
What would change your mind on DCO
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Missile and defense electronics demand stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the DCO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about DCO against your real portfolio and see your actual exposure before deciding.
Investing in Ducommun with AI
Connect the broker you already use and ask Walnut's AI how DCO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is DCO a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Missile and defense electronics demand, with revenue (ttm) at ~$865 million. The bear case rests on program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them. Analysts covering it are spread from $150.00 to $222.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell DCO?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $150.00, -25.5% from the $201.39 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for DCO?
+
Missile and defense electronics demand. Electronic Systems grew about 20% year over year in the second quarter of 2026, led by missile programs including PAC-3 and SM-6 plus F-15 work. The most optimistic analyst target on DCO is $222.00, +10.2% from the $201.39 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for DCO?
+
Program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them. Its customer list is short and includes Boeing, whose production has been unsteady, so a rate cut, a strike or a program termination flows straight through. The accounting is a live issue: the company said in May 2026 that its 2024 and 2025 statements should no longer be relied upon because of a stock-based compensation timing error, restated them, disclosed a material weakness in internal control over financial reporting, and at least two plaintiffs' firms opened investigations, which raises the odds of litigation and of further remediation cost. Defense revenue depends on appropriations and on continued urgency around munitions restocking, both of which are political rather than commercial variables. Finally, at roughly $3 billion of market value on about $865 million of sales, the shares already price the Vision 2027 margin outcome, so a missed quarter on Structural Systems or a slip in the margin trajectory has more room to hurt than to help. The most pessimistic published target is $150.00, -25.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Ducommun do?
+
Aerospace and defense supplier of structures and electronic assemblies, weighted toward military and space programs, targeting higher-margin engineered products.
What would have to change for DCO to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Missile and defense electronics demand) stalling in the reported numbers rather than in the narrative, the risk above (program concentration is the structural risk: a handful of platforms (the 737 MAX, the A320, PAC-3, SM-6, the F-15) drive a large share of revenue, and Ducommun does not control the build rates on any of them) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Ducommun do?
+
Ducommun is a Tier 2 aerospace and defense supplier. Its Electronic Systems segment builds circuit card assemblies, wire harnesses and cable, radar and microwave subsystems and printed circuit boards for missiles, radar, avionics and space hardware. Its Structural Systems segment makes metal and composite airframe structures, engine components and titanium parts. It sells to primes such as Raytheon, Lockheed Martin, Boeing, Airbus and Northrop Grumman rather than to end users.
Is Ducommun a defense stock or a commercial aerospace stock?
+
Both, currently tilted to defense. Military and space accounted for roughly 62% of the record $1.2 billion remaining performance obligation balance as of the second quarter of 2026, with commercial aerospace near 36% and a small industrial remainder. The defense side (missile programs like PAC-3 and SM-6, plus F-15 work) is growing much faster right now, while the commercial structures business tracks Boeing 737 MAX and Airbus A320 build rates.
What is Ducommun's Vision 2027 plan?
+
Vision 2027 is management's stated target set: roughly $1 billion in revenue, an 18% adjusted EBITDA margin, and more than 25% of sales from proprietary engineered products rather than build-to-print contract work. As of the second quarter of 2026, adjusted EBITDA margin was 17.1% and engineered products were about 23% of revenue, up from roughly 15% in 2022. The plan has been reaffirmed on recent earnings calls.
Walnut is informational, not investment advice, and gives no verdict on DCO. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.